$OSCR

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.

Oscar Health (OSCR) reported 2.96 million members in Q2 2026, up 46% YoY, driven by market share gains. Expansion plans include 150+ new areas by 2027. Challenges include seasonal enrollment and pricing pressures. The company focuses on profitability and retention over rapid growth.

Schlosser Mario sold 750,000 shares of Oscar Health, Inc. (OSCR) at an average of $30.43 ($30.34–$30.79, $22.82M total) across 2 trades over 2026-08-27 to 2026-08-28.

Zacks Value Investor Podcast highlights 3 stocks with growth and value: TD SYNNEX (SNX) reported record revenue, raised dividend; Oscar Health (OSCR) raised guidance, estimates; PBF Energy (PBF) reduced debt, saw earnings growth. All are Zacks #1 Rank (Strong Buy).

Oscar Health (OSCR) rose 3.1% today, driven by strong Q2 2026 results, including net income of $361.8M and improved earnings from operations. The company raised its full-year 2026 earnings outlook to $500M-$700M, citing better cost trends. Analysts increased targets, and insiders and hedge funds showed significant trading activity.

Oscar Health (OSCR) shareholder Mario T. Schlosser plans to sell 150,000 Class A shares worth $4.6M under Rule 144. The sale is tied to a stock option exercise set for 08/28/2026. Schlosser has sold 789,018 shares in the past three months, totaling $50.6M. The filing was signed by Gary Redman on behalf of Fidelity Brokerage Services.

Oscar Health (OSCR) has gained attention due to a Zacks Rank #1, rising earnings estimates, and a PEG ratio below industry average. Its share price has surged 108.68% year-to-date, with strong momentum. A popular narrative values the stock at $583.34, citing aggressive growth assumptions, but cautions about potential revenue slowdowns or margin pressures.

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

Oscar Health (OSCR) hit a 52-week high of $33.54, with a 90.7% total return over the past year. The company reported Q2 2026 adjusted earnings of $1.10 per share, beating estimates of $0.37, and revenue of $4.88 billion, exceeding expectations. InvestingPro suggests the stock may be overvalued, with a high beta of 2.39.

Oscar Health (OSCR) shares rose 12% to a 5-year high after the company reported strong Q1 earnings and optimistic guidance for 2026. CFO Scott Blackley cited favorable industry trends and potential upside to guidance, with membership growing 56% year-over-year to 3.17 million. The company's medical loss ratio improved to 70.5% from 75.4%. OSCR stock has gained 78% over the past year.